Rabeprazole sodium
Zulbex contains the active substance rabeprazole. It belongs to a group of medicines called proton pump inhibitors. The action of the medicine is to reduce the amount of acid produced by the stomach.
Zulbex is used for:
Before taking Zulbex, you should discuss it with your doctor or pharmacist.
You should inform your doctor or pharmacist:
If you get a rash on your skin, especially in areas exposed to sunlight, you should contact your doctor as soon as possible, as it may be necessary to stop taking Zulbex. You should also tell your doctor about any other side effects, such as joint pain.
In case of long-term use of the medicine, medical supervision may be necessary.
In some patients, problems with blood or liver have been observed, which usually disappeared after stopping treatment with rabeprazole.
If you experience diarrhoea (bloody or watery) with high fever and abdominal pain or tenderness while taking Zulbex, you should stop taking the medicine and contact your doctor immediately.
When taking proton pump inhibitors like Zulbex, especially for a period longer than one year, the risk of bone fractures in the hip, wrist or spine may increase slightly. You should inform your doctor if you have been diagnosed with osteoporosis or are taking corticosteroids (which can increase the risk of osteoporosis).
While taking rabeprazole, kidney inflammation may occur. Signs and symptoms may include decreased urine output or blood in the urine and (or) hypersensitivity reactions, such as fever, rash and joint stiffness. Such symptoms should be reported to the treating doctor.
Zulbex should not be used in children.
You should tell your doctor or pharmacist about all the medicines you are taking now or have taken recently, as well as about the medicines you plan to take.
You should inform your doctor or pharmacist:
If you are unsure whether the above situations apply to you, you should contact your doctor or pharmacist before taking Zulbex.
You should tell your doctor or pharmacist about all the medicines you are taking now or have taken recently, as well as about the medicines you plan to take.
Zulbex should not be taken during pregnancy or if you think you may be pregnant.
Zulbex should not be taken during breastfeeding or if you plan to breastfeed.
Taking Zulbex may cause drowsiness. In this case, you should not drive or operate machinery.
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means that it is essentially 'sodium-free'.
This medicine should always be taken exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
Zulbex is available in the following strengths: 10 mg, 20 mg.
ZULBEX TABLETS SHOULD BE SWALLOWED WHOLE.
ZULBEX TABLETS SHOULD NOT BE CRUSHED OR CHEWED.
The dosing below is usually used for adults and the elderly. Do not change the dose or duration of treatment yourself.
Zulbex should not be used in children.
Duodenal and benign gastric ulcers
The usual dose is one 20 mg Zulbex tablet per day.
In the case of duodenal ulcers, treatment should be continued for 4 weeks. After this time, your doctor may decide to extend the treatment for another 4 weeks. In the case of benign gastric ulcers, treatment should be continued for 6 weeks. After this time, your doctor may decide to extend the treatment for another 6 weeks.
Gastro-oesophageal reflux disease with oesophagitis or ulcers
The usual dose is one 20 mg Zulbex tablet per day. Treatment should be continued for 4 weeks. After this time, your doctor may decide to extend the treatment for another 4 weeks.
Long-term treatment of GORD
The usual dose is one 10 mg or 20 mg Zulbex tablet per day. Your doctor will decide how long you should take Zulbex. You should regularly consult your doctor to check your symptoms and dosage.
Symptomatic treatment of GORD
The usual dose is one 10 mg Zulbex tablet per day. It is recommended to use the fixed dose for 4 weeks. If symptoms do not disappear after this time, you should consult your doctor. After the first 4 weeks of treatment, if symptoms recur, your doctor may recommend taking one 10 mg Zulbex tablet on demand to control symptoms.
Zollinger-Ellison syndrome
The usual initial dose is 3 x 20 mg Zulbex tablets per day. The dose may be changed by your doctor during treatment, depending on your response to treatment. Your doctor will decide on the number of tablets to take and the duration of treatment. You should regularly consult your doctor to check your symptoms and dosage.
Treatment of H. pylori infection
The usual dose is 20 mg Zulbex (in combination with two antibiotics - clarithromycin 500 mg and amoxicillin 1 g) twice a day, usually for 7 days. Relief of symptoms usually occurs before the ulcer is completely healed. Therefore, it is important not to stop treatment until your doctor tells you to. For further information on other medicines used in H. pylori eradication, you should read the leaflet for the relevant medicine.
You should not take more tablets per day than your doctor has prescribed. If you have taken more tablets than prescribed, you should consult your doctor or go to hospital. You should take the tablets and packaging with you to hospital, so that the doctor can get information about the medicine you have taken.
If you miss a dose, you should take it as soon as possible, and then continue with your normal dosing schedule. If you have not taken the medicine for more than 5 days before taking it again, you should contact your doctor. You should not take a double dose to make up for a missed dose.
You should not change the dose or stop treatment without consulting your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Zulbex can cause side effects, although not everybody gets them.
Side effects are usually mild and disappear without the need to stop taking Zulbex.
You should stop taking Zulbex and contact your doctor immediately if you experience any of the following side effects, as you may need medical attention:
Other possible side effects:
If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Adverse Reaction Monitoring of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw
Tel.: + 48 22 49 21 301
Fax: + 48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
The batch number is stated on the packaging.
Store below 30°C. Store in the original packaging to protect from light and moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
20 mg gastro-resistant tablets: light brown-yellow, round, biconvex tablets, approximately 7.2 mm in diameter
Packaging: 28 gastro-resistant tablets in blisters, in a cardboard box.
For more detailed information, you should contact the marketing authorisation holder or parallel importer.
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorisation number in the Czech Republic, the country of export: 09/987/10-C
Parallel import authorisation number: 379/19
Austria | Rabeprazol Krka |
Cyprus | Rabeprazole Krka |
Germany, Spain | Rabeprazol TAD |
Netherlands | Rabeprazolnatrium Krka |
Italy | Rabeprazolo Krka |
Bulgaria, Czech Republic, Estonia, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia | Zulbex |
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.